Edition:
India

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

19.00USD
1:30am IST
Change (% chg)

$0.25 (+1.33%)
Prev Close
$18.75
Open
$18.75
Day's High
$19.00
Day's Low
$18.55
Volume
86,178
Avg. Vol
166,495
52-wk High
$20.35
52-wk Low
$11.90

Select another date:

Thu, May 3 2018

BRIEF-Vanda Pharmaceuticals Inc Reports Qtrly EPS Of $0.06

* VANDA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt

* U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT

BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule

* VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE

BRIEF-Vanda Pharma Prices Public Offering Of Common Stock

* ‍SALE OF 5.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING AT $17.00 PER SHARE​ Source text for Eikon: Further company coverage:

BRIEF-Vanda Pharmaceuticals Inc. Proposes Public Offering Of Common Stock

* VANDA PHARMACEUTICALS INC. PROPOSES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder

* HETLIOZ® (TASIMELTEON) DEMONSTRATES EFFICACY TO TREAT JET LAG DISORDER IN AN 8 HOUR PHASE ADVANCE CLINICAL STUDY

BRIEF-Vanda Pharmaceuticals Qtrly Net Loss Per Share $0.04

* VANDA PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS

Select another date: